EXELIXIS, INC. EXEL
- zanzalintinib — Colorectal Cancer NDA Submitted
- zanzalintinib — Non-Clear Cell Renal Cell Carcinoma Phase 3
- zanzalintinib — Renal Cell Carcinoma Phase 3
- zanzalintinib — Neuroendocrine Tumors Phase 3
- zanzalintinib — Meningioma Phase 2